咨询客服 咨询客服

Is Ultrafast or Abbreviated Breast MRI Ready for Prime Time?

Abstract:
Purpose of ReviewBreast MRI has been recognized as the most sensitive modality for breast cancer screening. Its use is, however, restricted due to the high costs of the MRI scan itself, the limited availability of MRI scanners and the long reading times. In this review, the use of shorter MRI protocols for screening is discussed.Recent FindingsShortened scan protocols have been proposed to reduce both the actual patient handling time and the time to evaluate the scan. So far, these “abbreviated” scan protocols have shown similar sensitivity and only marginally lower specificity as the common scan protocols, while largely reducing scan time and time required for evaluation. To retain the dynamic information, ultrafast dynamic breast MRI was introduced, capturing the inflow of contrast in a lesion. This comes for free in terms of scan time. The diagnostic information from this dynamic evaluation is even stronger than the conventional curve types and can be exceptionally helpful in the evaluation of small lesions. Since abbreviated and ultrafast MRIs are not mutually exclusive, both techniques can be combined, yielding a screening protocol with a scan time below 5\xa0min. However, only very few studies evaluated these protocols in a true screening setting, and the number of detected cancers is likewise very low.SummaryAbbreviated protocols with ultrafast MRI allow shortening of breast MRI for screening while retaining excellent sensitivity and specificity. Prospective study data are however limited and must be further substantiated.
Author Listing: Ritse M. Mann;Jan van Zelst;Suzan Vreemann;Roel Mus
Volume: 11
Pages: 9-16
DOI: 10.1007/s12609-019-0300-8
Language: English
Journal: Current Breast Cancer Reports

Current Breast Cancer Reports

CURR BREAST CANCER R

影响因子:0.9
是否综述期刊:否
是否OA:否
是否预警:不在预警名单内
发行时间:-
ISSN:1943-4588
发刊频率:4 issues per year
收录数据库:ESCI/Scopus收录
出版国家/地区:-
出版社:Springer Nature

期刊介绍

This journal aims to review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of breast cancer. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those with the disease. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as prevention, systemic therapy, and translational research. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

本杂志旨在回顾最近发表的与乳腺癌的诊断、治疗、管理和预防相关的最重要的临床发现。通过提供国际专家清晰、有见地、平衡的贡献,该杂志打算为所有参与护理该疾病患者的人服务。我们通过任命国际权威机构担任关键主题领域的编辑来实现这一目标,如预防、系统治疗和转化研究。而版块编辑则会选择一些主题,让顶尖专家为这些主题撰写全面的评论文章,这些文章强调新的发展和最近发表的重要论文,并通过注释参考文献列表突出显示。一个国际编辑委员会审查年度目录,建议他们国家/地区特别感兴趣的文章,并确保主题是最新的,包括新兴的研究。还提供了该领域知名人士的评论。

年发文量 48
国人发稿量 -
国人发文占比 0%
自引率 11.1%
平均录取率 -
平均审稿周期 -
版面费 US$3280
偏重研究方向 ONCOLOGY-
期刊官网 https://www.springer.com/12609/?utm_medium=display&utm_source=letpub&utm_content=text_link&utm_term=null&utm_campaign=MLSR_12609_AWA1_CN_CNPL_letpb_mp
投稿链接 https://www.editorialmanager.com/CBCR

质量指标占比

研究类文章占比 OA被引用占比 撤稿占比 出版后修正文章占比
6.25% 13.33% - -

相关指数

影响因子
影响因子
年发文量
自引率
Cite Score

预警情况

时间 预警情况
2025年03月发布的2025版 不在预警名单中
2024年02月发布的2024版 不在预警名单中
2023年01月发布的2023版 不在预警名单中
2021年12月发布的2021版 不在预警名单中
2020年12月发布的2020版 不在预警名单中

JCR分区 WOS分区等级:Q4区

版本 按学科 分区
WOS期刊SCI分区
(2021-2022年最新版)
ONCOLOGY Q4

中科院分区

版本 大类学科 小类学科 Top期刊 综述期刊
暂无数据